Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is hepatic steatosis (fat in more than 5% of hepatocytes) occurring in a patient with at least one of five cardiometabolic risk factors — overweight/obesity, impaired glucose regulation or type 2 diabetes, hypertension, elevated triglycerides, or low HDL cholesterol — and without another explanation for the steatosis (significant alcohol use, another liver disease, or a steatogenic medication).^[1] The name replaces "nonalcoholic fatty liver disease (NAFLD)" — a 2023 multisociety Delphi consensus involving 236 panellists from 56 countries found the old terminology stigmatizing and diagnostically backwards (defined by what it isn't rather than what it is), and formally adopted MASLD, with MASH (metabolic dysfunction-associated steatohepatitis) replacing NASH for the inflammatory, more fibrogenic subtype. A related but distinct category, MetALD, describes patients who meet the cardiometabolic criteria for MASLD but also drink more alcohol than the MASLD definition allows (roughly 140-350 g/week for women, 210-420 g/week for men) — a mixed-etiology group that needs both metabolic and alcohol-focused counselling.^[1]

MASLD is common — an estimated 30% of North American adults have some degree of it — and it is now the fastest-growing cause of cirrhosis, hepatocellular carcinoma, and liver transplantation in North America, a trajectory that tracks directly with rising obesity and type 2 diabetes prevalence. Most patients are asymptomatic and are identified incidentally — mildly elevated ALT/AST on routine bloodwork, or steatosis noted on an abdominal ultrasound or CT ordered for an unrelated reason — which means the people best positioned to catch it early are often not hepatologists but primary care and community pharmacy.^[2] The great majority of MASLD never progresses to serious liver disease; the goal of assessment is not to label every patient with fatty liver, but to correctly identify the roughly 20-30% with MASH and the smaller subset with clinically significant fibrosis (stage F2 or higher) who are the ones actually at risk of liver-related morbidity and mortality and who benefit most from structured intervention.

Liver biopsy, Masson's trichrome stain: large clear lipid droplets (macrovesicular steatosis) displacing hepatocyte nuclei, concentrated in the centrilobular zone, with mild green-stained fibrosis. This histologic appearance is what "steatosis," and — when accompanied by ballooning and inflammation — "steatohepatitis (MASH)," actually look like under the microscope. (Nephron, CC BY-SA 3.0, Wikimedia Commons)

Typical presentation

The overwhelming majority of patients with MASLD have no symptoms at all. When something is noticed, it is usually one of: vague right-upper-quadrant discomfort or fullness, unexplained fatigue, or an incidental finding — mildly elevated ALT/AST on routine labs (often ordered for diabetes or cardiovascular risk monitoring, not for the liver), or hepatic steatosis reported on an ultrasound, CT, or MRI done for an unrelated reason. A patient can have completely normal liver enzymes and still have MASH or even advanced fibrosis — normal ALT does not rule out clinically significant disease, which is exactly why risk-factor-based case finding (see Assessment & Diagnosis), not symptom- or enzyme-based suspicion alone, is the recommended approach.^[2]

MASLD, MASH, and fibrosis are not the same thing

A patient can have severe steatosis with completely normal fibrosis, or comparatively mild-looking steatosis with advanced fibrosis — imaging and enzymes alone cannot distinguish these, which is precisely the gap FIB-4-based staging is designed to close.

Cardiometabolic risk factors (any one, alongside steatosis, meets the MASLD definition)

• Overweight/obesity, particularly central/visceral adiposity.
• Type 2 diabetes or prediabetes/insulin resistance — the single most impactful risk factor for both developing MASLD and for fibrosis progression, hepatocellular carcinoma, and liver-related mortality once MASLD is present.^[3]
• Hypertension.
• Elevated triglycerides.
• Low HDL cholesterol.

Who actually warrants case finding

Per current Canadian multidisciplinary guidance, prioritize risk-factor-based case finding — not universal population screening — in:

• Type 2 diabetes (the single highest-yield group to case-find in).
• Two or more of the cardiometabolic risk factors above (central obesity, high triglycerides, low HDL, hypertension, prediabetes/insulin resistance).
• Elevated aminotransferases with no other clear explanation.
• Incidental imaging findings of hepatic steatosis on any modality.^[2]

Other contributors and modifiers

• Polycystic ovary syndrome, obstructive sleep apnea, and hypothyroidism are all independently associated with MASLD and worth asking about.
• Sarcopenia and a sedentary lifestyle independently accelerate fibrosis progression, even after accounting for BMI.
• Genetic modifiers (e.g., PNPLA3 variants) influence individual risk but are not part of routine clinical assessment.
• A family history of cirrhosis or hepatocellular carcinoma in a first-degree relative with MASLD raises the index of suspicion for that patient's own fibrosis risk.
• Concurrent alcohol use above the MASLD-definition threshold shifts the diagnosis toward MetALD or alcohol-associated liver disease rather than pure MASLD, and needs its own counselling track.^[1]

Step 1 — confirm steatosis and exclude other causes

• Steatosis is usually first identified on ultrasound, CT, or MRI ordered for another reason, or suspected from elevated ALT/AST in a patient with cardiometabolic risk factors.
• Take a careful alcohol history — quantify actual weekly intake, since the MASLD/MetALD/alcohol-associated liver disease distinction depends on it.^[1]
• Review medications for steatogenic culprits (e.g., amiodarone, methotrexate, tamoxifen, corticosteroids, valproate) and consider viral hepatitis serologies, ferritin/transferrin saturation, and — where the clinical picture is atypical (young age, disproportionate enzyme elevation, low ceruloplasmin) — screening for autoimmune or genetic liver disease, per the treating clinician's judgment.

Step 2 — calculate FIB-4

FIB-4 is age-sensitive at the extremes: it is not considered reliable in patients aged 35 or younger (routinely overestimates risk at this age) and current Canadian guidance recommends a lower low-risk cutoff of 2.0 (rather than 1.3) in patients aged 65 and older, since FIB-4 rises with normal aging independent of fibrosis. The age-stratified thresholds should be applied rather than the standard adult cutoffs outside the 36-65 age range.^[2] Thrombocytopenia from an unrelated cause, active alcohol use, acute hepatic inflammation, and chronic kidney disease can each falsely alter the FIB-4 score and should be considered when interpreting an unexpected result.

Step 3 — imaging-based liver stiffness measurement for indeterminate FIB-4

Transient elastography (vibration-controlled transient elastography, e.g. FibroScan), shear wave elastography, and MR elastography all provide comparable diagnostic accuracy for fibrosis staging; the practical choice in most Canadian settings is transient elastography or shear wave elastography based on local availability, with MR elastography reserved for indeterminate or discordant results given its higher cost and lower availability.^[2]

If FIB-4 was not available before elastography, the "rules in/rules out" thresholds shift slightly: <5 kPa is low risk, 5-13 kPa is indeterminate, and >13 kPa rules in advanced disease and warrants specialist referral.^[2]

Liver biopsy

Reserved for genuinely indeterminate or discordant noninvasive results, or when confirming a MASH diagnosis (rather than simple steatosis) would specifically change management — for example before starting pioglitazone or vitamin E, both of which are only recommended for biopsy-proven MASH (see Pharmacologic Treatment Options). Biopsy is not required to diagnose or manage most patients with MASLD.

• Achieve and sustain 7-10% total body weight loss — the single most effective, evidence-based intervention for reversing steatohepatitis and fibrosis.
• Optimize every coexisting cardiometabolic risk factor (glycemic control, blood pressure, lipids) — cardiovascular disease, not liver disease, is the leading cause of death in MASLD, and this remains true even in patients with advanced fibrosis.
• Correctly identify the subset of patients with MASH and clinically significant fibrosis (F2 or higher) who benefit from structured pharmacotherapy, without over-medicalizing the much larger group with steatosis alone.
• Prevent progression to cirrhosis, hepatocellular carcinoma, and decompensation through appropriate staging and monitoring intervals.
• Correct the common misconception that statins are unsafe in liver disease — untreated dyslipidemia, not the statin itself, is the real cardiovascular threat in this population.

• Structured weight loss targeting 7-10% of total body weight — a Mediterranean-pattern diet (emphasizing vegetables, legumes, whole grains, olive oil, and reduced red meat/refined carbohydrate) has the strongest evidence specifically for MASLD/MASH, independent of its caloric effect.
• Reduce or eliminate fructose-sweetened beverages specifically — high fructose intake is independently associated with steatosis and fibrosis progression beyond its caloric contribution.
• Regular physical activity — at least 150 minutes/week of moderate-intensity aerobic activity, which improves steatosis even without significant weight loss, plus resistance training to preserve muscle mass (sarcopenia independently worsens outcomes).
• Limit alcohol — while MASLD by definition permits some alcohol intake below the MetALD threshold, lower intake is better for liver outcomes, and any patient with more advanced fibrosis should be counselled toward abstinence.
• Referral to a structured, ideally multidisciplinary, weight-management program (dietitian involvement, and behavioural support) rather than relying on brief unsupported advice — coached programs consistently outperform self-directed attempts at achieving and sustaining the 7-10% target.
• Bariatric surgery is a reasonable option for patients who otherwise meet standard bariatric-surgery eligibility criteria and produces substantial, durable improvement in steatohepatitis and fibrosis; it is not itself a liver-specific intervention but a route to the sustained major weight loss that drives liver benefit.
• Sleep and OSA screening — obstructive sleep apnea is independently associated with MASLD severity and is frequently under-recognized in this population.

Older adults

FIB-4 rises with normal aging independent of true fibrosis — apply the age-adjusted low-risk cutoff of <2.0 (rather than <1.3) in patients 65 and older to avoid over-referring on the basis of age alone.^[2] Weigh pioglitazone's fracture and fluid-retention risks, and vitamin E's evidence gaps, more heavily in this group; a structured weight-management referral should still account for frailty and sarcopenia risk rather than pursuing aggressive caloric restriction indiscriminately.

Younger adults (age ≤35)

Standard FIB-4 thresholds are not considered reliable in this age group and tend to overestimate fibrosis risk; a family physician or hepatologist should interpret an abnormal FIB-4 result in a young adult with additional caution rather than applying the standard cutoffs directly.^[2]

Type 2 diabetes

The single highest-risk group for both MASLD development and fibrosis progression — case-find with FIB-4 at diagnosis and periodically thereafter regardless of symptoms or enzyme levels.^[3] Vitamin E is not recommended in this group (no evidence base in diabetics); pioglitazone and semaglutide both have data specifically supporting their use here, and both also independently benefit glycemic control.

Compensated vs. decompensated cirrhosis

Statins remain appropriate in compensated MASLD-cirrhosis and should not be withheld.^[3] Once decompensation occurs (ascites, jaundice, variceal bleeding, encephalopathy), management shifts to decompensated-cirrhosis-specific care — portal hypertension management, transplant evaluation, hepatocellular carcinoma surveillance — which is covered in the separately-authored Cirrhosis chapter rather than duplicated here; refer promptly rather than continuing to manage a decompensating patient within a MASLD-focused framework.

Pregnancy

Weight-loss pharmacotherapy (including semaglutide) and pioglitazone are not used in pregnancy; structured lifestyle counselling remains appropriate. A patient with known MASLD who becomes pregnant should have her liver-related monitoring plan reviewed with her obstetric team, since pregnancy itself can be complicated by distinct liver conditions (e.g., acute fatty liver of pregnancy, HELLP) that are not MASLD and need their own urgent recognition.

Renal impairment

Semaglutide requires no specific renal dose adjustment but should be used cautiously in patients with a history of significant GI fluid losses given theoretical dehydration/renal risk. Pioglitazone's fluid-retention effect warrants extra caution in any degree of renal or cardiac impairment.

• Low risk (FIB-4 below the age-adjusted cutoff, or elastography <8 kPa): repeat FIB-4 in 1-3 years, sooner if new risk factors develop or existing ones worsen (e.g., new T2DM diagnosis, significant weight gain).^[2]
• Indeterminate risk, managed without specialist referral: reassess according to the plan set by whoever performed the elastography/biopsy work-up — typically closer surveillance than the low-risk interval, with a lower threshold to re-image or refer if enzymes rise or new symptoms develop.
• High risk / under specialist care: follow the hepatology-directed monitoring plan, which typically includes periodic elastography, hepatocellular carcinoma surveillance once cirrhosis is confirmed, and variceal screening per standard cirrhosis protocols.
• Reassess weight, waist circumference, and every cardiometabolic parameter (A1c, blood pressure, lipid panel) at routine intervals regardless of fibrosis risk category — these drive both liver and cardiovascular outcomes.
• For a patient started on pioglitazone or vitamin E: confirm the original MASH diagnosis was genuinely biopsy-confirmed, and reassess at the interval the prescriber set (pivotal trial data used roughly 96 weeks of vitamin E to demonstrate histologic benefit) rather than expecting a rapid symptomatic response, since these agents are titrated to histologic, not symptomatic, endpoints.
• For semaglutide specifically: monitor per its standard T2DM/weight-management titration and tolerability schedule; the liver-specific benefit is a slower, longer-term histologic outcome, not something to expect to see reflected quickly in liver enzymes alone.

1. Weight loss target not being met despite counselling — escalate from unsupported advice to a structured, ideally multidisciplinary weight-management program (dietitian, behavioural support) before concluding the patient "isn't responding"; unsupported self-directed attempts have a low success rate at sustaining 7-10% loss.
2. FIB-4 or elastography result is indeterminate or discordant with the clinical picture — proceed to the next step in the pathway (MR elastography, biopsy, or specialist referral) rather than repeating the same test and hoping for a clearer answer.^[2]
3. Confirmed MASH not improving on pioglitazone or vitamin E after an adequate trial — reassess adherence and weight-loss progress (pharmacotherapy is an adjunct to, not a replacement for, lifestyle intervention), then involve hepatology to consider semaglutide or another approach rather than continuing an ineffective regimen indefinitely.
4. Rising FIB-4, worsening elastography, or new clinical signs of advancing disease despite intervention — refer (or re-refer) to hepatology promptly; this pattern suggests the patient needs closer specialist-level monitoring than a primary-care/pharmacy-led pathway can provide.
5. Any sign of decompensation emerging during follow-up (new ascites, jaundice, confusion, GI bleeding) — this is an urgent referral, not a "monitor and reassess at the next visit" situation; see Red Flags & Refer.

• Withholding or stopping a clinically indicated statin because of a fatty-liver diagnosis or a mildly elevated ALT — statins are not contraindicated in MASLD/MASH, including compensated cirrhosis, and cardiovascular disease is this population's leading cause of death.^[3]
• Assuming a normal ALT rules out significant disease — a substantial proportion of patients with MASH or even advanced fibrosis have normal liver enzymes; risk-factor-based case finding with FIB-4, not enzyme-based suspicion, is the recommended approach.
• Applying standard-adult FIB-4 cutoffs without adjustment in a patient under 35 or 65 and older, where age-adjusted interpretation is needed to avoid under- or over-referral.^[2]
• Starting vitamin E in a patient with diabetes, or in a patient without biopsy-confirmed MASH — neither situation has supporting evidence, and the mortality/prostate-cancer safety signals mean it should not be reached for casually.
• Telling a patient that resmetirom is an option in Canada — it is FDA-approved in the U.S. only; as of this writing it has no Health Canada Notice of Compliance and is not prescribable or reimbursed here.
• Treating semaglutide's new MASH indication as identical to its existing T2DM/weight-management indications — confirm which indication and coverage pathway actually applies for a given patient rather than assuming interchangeability.
• Giving generic "eat less, move more" advice instead of referring to a structured weight-management program — unsupported self-directed attempts rarely achieve or sustain the 7-10% body-weight loss needed for histologic improvement.
• Missing an alternative or coexisting liver disease (viral hepatitis, hemochromatosis, autoimmune hepatitis) by assuming every patient with steatosis and a cardiometabolic risk factor has MASLD and nothing else — red-flag features (AST:ALT >1, very high transaminases, atypical age or presentation) warrant their own work-up.
• Continuing to manage a patient within a MASLD-focused framework after signs of decompensation appear, rather than promptly escalating to cirrhosis-specific/hepatology care.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Health Canada-authorized MASH-specific pharmacotherapy

Reserved for biopsy-proven MASH with fibrosis stage F2-F3 (non-cirrhotic) — not for steatosis alone.

Biopsy-proven MASH — alternative pharmacotherapy

Both require histologic confirmation of MASH before starting; neither is appropriate for steatosis alone.

Cardiometabolic therapy in MASLD/MASH — correcting the statin-safety misconception

MASLD/MASH does not change the indication, dosing, or monitoring for standard cardiometabolic therapy; the only genuinely MASLD-specific point is that statins should not be withheld.